Nationality: Switzerland
Year of birth: 1964
Position: Chairman of the Board of Directors
Member¹ since: 2020

Gilbert Achermann, member of the Board of Directors of Ypsomed Holding AG and member of the Nomination & Compensation Committee (NCC), the Audit & Risk Committee (ARC) as well as the Innovation & Sustainability Committee (ISC). 

After completing his banking apprenticeship at the Bankverein and the HWV in St. Gallen, Gilbert Achermann worked in investment banking at UBS in Switzerland and abroad from 1988 to 1998. 

In 1998 he moved to the MedTech industry as CFO at Straumann, where he was appointed CEO in 2002 and acted as Chairman of the Board of Directors of Straumann Holding AG from 2010 until April 2024. 

In addition, Gilbert Achermann was Chairman of the Board of Directors of Siegfried Holding AG in Zofingen (2011 to 2014) and Vitra Holding AG in Birsfelden (2012 to 2015). 

From 2012 to April 2024, he was a member of the Board of Directors of the private bank Julius Baer. From 2016 until May 2024, he was a member of the Committee of the Basle Chamber of Commerce and since 2016 he has been a member of the Supervisory Board of IMD – International Institute for Management Development in Lausanne. Since 2020, he has been a member of the Board of Directors of Swiss Medtech, since 2022 a member of the Board of Directors of greenTEG AG in Rümlang, since 2023 Chairman of the Board of Directors of Unilabs in Copenhagen, Denmark, and since 2024 a member of the Board of Directors of Sonova Holding AG. 

He is also involved in Venture Kick as a juror and is an active investor in Swiss start-ups. 

Nationality: French-German
Year of birth: 1970
Position: Member of the Board of Directors
Member¹ since: 2025

Marie-Pierre Zerr, member of the Board of Directors of Ypsomed Holding AG and Chairwoman of the Innovation & Sustainability Committee (ISC).

As Vice President Global Process Engineering of Stellantis, Marie-Pierre Zerr is responsible for the areas logistics, production planning as well as conveyor and automation technology – from the strategy phase to the industrialisation of highly flexible production processes and innovative technologies. Furthermore, she leads the global Energy Business Unit and the production of autonomous transport systems. Previously, she held several leadership positions at Mercedes-Benz Cars Operations and Daimler Trucks Operations – including as Production Manager, Global Head of Operating System & Industry 4.0 and in the area Operational Excellence. In these positions, she implemented significant efficiency improvements throughout the entire value chain.

Marie-Pierre Zerr holds a degree in Chemical Engineering with a specialisation in plastics technology from the École Nationale Supérieure de Mulhouse. She was born in 1970, is married and holds a dual French-German citizenship.

Nationality: US and Belgium
Year of birth: 1961
Position: Member of the Board of Directors
Member¹ since: 2018

Paul Fonteyne, member and Vice Chairman of the Board of Directors of Ypsomed Holding AG as well as chairman of the Nomination & Compensation Committee (NCC). 

After graduating from Brussels University with a degree in chemical engineering and an MBA from Carnegie Mellon University in Pittsburgh, Paul Fonteyne held various positions at Abbott Laboratories Inc. and Merck and Co. Inc. 

He joined the Boehringer Ingelheim Group in 2003. For the first five years, he headed the Human Pharmaceuticals Division in the USA. Afterwards, he lead the worldwide marketing team for human pharmaceuticals in Germany from 2008 to 2011. From 2012 to 2018, he was Chairman of the Board of Directors and CEO of Boehringer Ingelheim USA as well as Country Managing Director for the United States. 

Paul Fonteyne previously served as Chairman of the National Pharmaceutical Council (NPC) and was a member of the Board of Directors of Pharmaceutical Research and Manufacturers of America (PhRMA), of ResTORbio Inc. (until 2020) of AMAG Pharmaceuticals Inc. (until 2020), of Covetrus Inc. (until 2022) and of Gelesis Inc (until 2023). 

Paul Fonteyne is currently a member of the Board of Directors of the four biotechnology companies Amylyx Pharmaceuticals Inc., Apnimed Inc. and Appelis Pharmaceuticals Inc., all based in the USA, as well as DalCor Inc., based in London. Since April 2024, he has been Chairman of the Board of Directors of Corium Therapeutics Inc., USA.  

Furthermore, he is associated with Canaan Partners (Venture Capital) as Executive in Residence. 

Nationality: Germany and Switzerland
Year of birth: 1970
Position: Member of the Board of Directors
Member¹ since: 2019

Dr. Martin Münchbach, member of the Board of Directors of Ypsomed Holding AG and Chairman of the Audit & Risk Committee (ARC). 

After graduating from ETH Zurich with a degree in natural sciences followed by a doctorate (Dr. sc. nat.) in protein chemistry and with further postgraduate studies in economics, business and management sciences from ETH Zurich, he worked in various functions at venture capital firms in Switzerland. 

He is currently Managing Partner of Pureos Bioventures, a venture capital firm specializing in early-stage financing to support innovative young drug development companies with a focus on Switzerland and Europe. Through his involvement as a venture capitalist, he has been able to establish numerous medical technology and biotechnology companies that have brought innovative drugs and diagnostics to market approval. 

Martin Münchbach was a member of the Board of Directors of Alentis Therapeutics AG in Basel until 2024 and is presently a member of the Board of Directors of Ariceum Therapeutics in Berlin, Germany and of River Renal Inc. in New York, USA. 

Nationality: Switzerland
Year of birth: 1977
Position: Member of the Board of Directors
Member² since: 2022

Simon Michel, member of the Board of Directors of Ypsomed Holding AG and CEO of the Ypsomed Holding AG. Member of the Audit & Risk Committee (ARC) as well as the Innovation & Sustainability Committee (ISC). 

Simon Michel is with Ypsomed since October 2006 and a member of the Executive Board since 2008, where he was initially responsible for Marketing & Sales. Since July 2014, he has been CEO of Ypsomed Holding AG. 

From 2003 until 2006, Simon Michel worked for Orange Communications AG. 

Simon Michel studied economics at the University of St. Gallen and completed a Master's degree with a focus on media and communications management. 
Until 2024 he was a member of the Board of Directors of Unitectra AG and siteminsel AG. He is a member of the Board of Directors of Forster Rohner AG and LEM Surgical AG. Since 2017, he has been Chairman of the Board of Directors of DCB Research AG, which works closely with the University Hospital UDEM of the Insel Group in Switzerland and conducts research into new therapeutic approaches to treat diabetes. Since 2021, he has also been Chairman of the Board of Directors of Ahueni AG, a company involved in the development and trading of CO2 certificates in Africa. 

Simon Michel is on the Board of the Cantonal Bernese Trade and Industry Association and the Solothurn Chamber of Commerce and has been a Board member of Swiss Medtech since 2015. Since 2023, he has been on the Board Committee of economiesuisse and on the Board of progresuisse since 2024. In autumn 2023, he was elected to the National Council of the Swiss Confederation. 

Nationality: Switzerland
Year of birth: 1977
Position: CEO of the Ypsomed Holding AG
At Ypsomed since: 2006

Simon Michel is member of Executive Board since 2008, where he was initially responsible for Marketing & Sales. He has been CEO since July 2014 and member of the Board of Directors of Ypsomed Holding AG since June 2022. 

From 2003 until 2006, Simon Michel worked for Orange Communications AG. 

Simon Michel studied economics at the University of St. Gallen and completed a Master's degree with a focus on media and communications management. 

Until 2024 he was a member of the Board of Directors of Unitectra AG and siteminsel AG. He is a member of the Board of Directors of Forster Rohner AG and LEM Surgical AG. Since 2017, he has been Chairman of the Board of Directors of DCB Research AG, which works closely with the University Hospital UDEM of the Insel Group in Switzerland and conducts research into new therapeutic approaches to treat diabetes. Since 2021, he has also been Chairman of the Board of Directors of Ahueni AG, a company involved in the development and trading of CO2 certificates in Africa. 

Simon Michel is on the Board of the Cantonal Bernese Trade and Industry Association and the Solothurn Chamber of Commerce and has been a Board member of Swiss Medtech since 2015. Since 2023, he has been on the Board Committee of economiesuisse and on the Board of progresuisse since 2024. In autumn 2023, he was elected to the National Council of the Swiss Confederation. 

Nationality: Germany and Switzerland
Year of birth: 1969
Position: Chief Business Officer (CBO) YDS
At Ypsomed since: 2001

Ulrike Bauer is with Ypsomed (resp. Disetronic before 2003) since 2001 in various marketing and sales functions. Since 2014, she is a member of the Executive Board and responsible for the Delivery Systems business unit. Previously, she was Product Manager with Mettler Toledo (1996 – 2001) among other things. 

She has a degree (Dipl. Ing.) in chemical engineering and biotechnology at the University of Applied Sciences Aachen as well as a postgraduate diploma in International Management at the Kalaidos University of Applied Sciences in Zurich.

Nationality: Switzerland
Year of birth: 1984
Position: Chief Financial Officer (CFO)
At Ypsomed since: 2024

Samuel Künzli is a certified auditor and holds a Master’s degree in Accounting and Corporate Finance from the University of St. Gallen (HSG). Before joining Ypsomed, he spent three years as CFO at Feintool. From 2012 to 2020, he held various managerial functions in finance at Stadler, including as CFO for Central Europe and most recently as CFO of the Swiss division. Samuel Künzli worked at KPMG Switzerland from 2008 to 2012 as an auditor. Samuel Künzli is Chairman of the Board of Directors of Tewo-Treuhand AG since 2021 and Chairman of the Board of Directors of Frista Retail AG since June 2024.

Nationality: Germany and Switzerland
Year of birth: 1964
Position: Chief Operating Officer (COO)
At Ypsomed since: 2015

Frank Mengis joined Ypsomed in 2015 as a member of the Executive Board, responsible for the areas Production, Supply Chain and QM&RA. 

He comes with many years of experience in the development and production of medical devices: previously he was COO and member of the Executive Management of Nobel Biocare AG, responsible for the production sites worldwide and the global supply chain. In the years 2001 to 2012 he held various management functions in the Straumann Group in Switzerland and the USA in the areas of quality management, production and development. 

After graduating, he started his career at F. Hoffmann La Roche AG in Basel in the Engineering Department (1990 – 1999). Of German-Swiss dual nationality, he graduated as Dipl. Ing. Mechanical Engineering from the Technical University Karlsruhe followed by further training at both the IMD Lausanne and the Harvard Business School (AMP Programme). 

From 2017 to 2021 he was a member of the Board of Directors at Qualitech AG. He has also been a member of the Board of Directors of Nemis Technologies AG since 2021.

Nationality: Switzerland
Year of birth: 1972
Position: Chief Corporate Officer (CCO)
At Ypsomed since: 2017

Michael Zaugg has been with Ypsomed since 2017 and is also Chairman of the Board of Trustees of the Ypsomed Group Pension Fund Foundation since 2020. From 2011 to 2017 he was employed as Head of Talent Europe at ABB. Previously he worked in HR at Credit Suisse (1997 to 2004), was Consultant and Executive Board member at schärpartners ag (2004 to 2007), Head of HR Services at Valiant Holding (2007 to 2008) and Head of HR Recruiting at BKW FMB AG (2008 to 2011). 

Michael Zaugg studied economics at the University of Basel (degree: lic.rer. pol) specialising in human resources management, marketing and environmental economics. He also holds a degree from the university’s crossfaculty accompanying study programme Man – Society – Environment (MSE) and an Executive Master of Human Resources Management from the Institute of Applied Psychology in Zurich.

Nationality: Switzerland
Year of birth: 1971
Position: Chief Legal Officer (CLO)
At Ypsomed since: 2023

Dr. Nicolas Meyer joined Ypsomed in 2023 as CLO and Secretary of the Board of Directors of Ypsomed Holding AG. Previously, Nicolas Meyer was General Counsel and Secretary General at RUAG MRO for three years. From 2010 to 2018, he was General Counsel at the EMS Group and previously worked as a lawyer at Lenz Caemmerer in Basel for close to seven years. Nicolas Meyer obtained his Master of Law from the University of Basel in 1997 and was admitted to the bar in 2001. In 2004, he earned a doctorate in intellectual property law, and in 2024, he received an Executive MBA in General Management from the University of St. Gallen (HSG). Since 2024, Nicolas Meyer has been on the Legal Committee of the Swiss-American Chamber of Commerce.